Angiotensin(1 –7) Improves Islet Function in Diabetes Through Reducing JNK/Caspase-3 Signaling

Horm Metab Res 2022; 54: 250-258 DOI: 10.1055/a-1796-9286The aim of this study is to investigate whether Angiotensin (1–7), the physiological antagonist of Angiotensin II (AngII), has antidiabetic activity and the possible mechanism. Male Wistar rats were randomly divided into 3 groups: control group fed the normal diet, DM group fed high-fat diet and injected with STZ, and Angiotensin (1–7) group receiving injection of STZ followed by Angiotensin (1–7) treatment. Serum Ang II, fasting blood glucose, insulin, HOMA-IR, and HOMA-beta were determined in control, diabetes and Angiotensin (1–7) groups. The increased AngII and insulin resistance in diabetes group were accompanied by changes in islet histopathology. However, Angiotensin (1–7) improved the islet function and histopathology in diabetes without affecting the level of AngII. Western blot confirmed that Angiotensin (1–7) decreased the cleaved caspase 3 levels in pancreas of DM. The increased expression of JNK, Bax, and Bcl2 genes under diabetic conditions were partially reversed after Angiotensin (1–7) administration in pancreas. Immunofluorescence analysis showed that p-JNK was markedly increased in islet of DM rats, which was markedly alleviated after Angiotensin (1–7) treatment. Furthermore, Angiotensin (1–7) reversed high glucose(HG...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Tags: Original Article: Endocrine Research Source Type: research